MedX Announces Final Closing of Non-Brokered Private Placement

Core Viewpoint - MedX Health Corp. has successfully completed the final closing of a non-brokered private placement, raising a total of $1,433,000 through the issuance of 19,106,666 units, which will be used for the development of its telemedicine platform and other corporate purposes [1][2]. Group 1: Private Placement Details - The final closing involved the issuance of 19,106,666 units at a price of $0.075 per unit, bringing the total units issued in this placement to 26,139,999 [1]. - Each unit consists of one fully paid common share and one-half share purchase warrant, with each whole warrant exercisable at $0.10 for one additional common share within one year [1]. - Insiders participated in the placement, acquiring a total of 21,806,666 units for $1,635,500, relying on exemptions from formal valuation and minority shareholder approval [1]. Group 2: Use of Funds - Funds raised from the private placement will be directed towards the continued development of the SIAscopy® technology on the DermSecure® telemedicine platform, expanding its launch into the occupational health market, and for general corporate purposes [2]. Group 3: Company Overview - MedX Health Corp. is a leader in non-invasive skin assessment and teledermatology, with its proprietary SIAscopy® technology enabling accurate imaging of skin lesions for rapid dermatologist review [3]. - The company's products are approved for use in multiple regions, including Canada, the U.S., Australia, and the European Union, highlighting its regulatory compliance and market reach [3]. - MedX's telemedicine platform allows healthcare professionals to assess skin conditions efficiently through its advanced imaging technology and secure patient management system [3].